What is it? FDA regulations Type 2 Diabetes
The purpose of this guidance is to provide the Food and Drug Administration’s (FDA’s) current recommendations regarding the overall evaluation of safety for the development of drugs and biologics indicated for the improvement of glycemic control in patients with type 2 diabetes mellitus. The recommendations in this guidance reflect discussions at the Endocrinologic and Metabolic Drugs Advisory Committee meeting held October 24–25, 2018, that considered FDA’s review of cardiovascular (CV) outcome trials (CVOTs).
Comment by Cherry Biotech:-
Introduction MPS (Multiorgan Microphysiological Systems) have evolved from tools to reduce animal experimentation and improve…
Introduction Melanoma is clearly a complex disease with a high degree of heterogeneity and adaptability.…
Introduction The researchers created a microfluidic organ-on-chip solution with integrated electrochemical microsensor arrays enabling compartmentalized…
Introduction Animal models and two-dimensional (2D) cell cultures frequently fail to replicate human drug metabolism…
Introduction Adipose Tissue is very versatile and essential for studies related to Obesity and Diabetes,…
Introduction The state of the art for tissues-on-chips using skin cells had been lacking for…